IP Library › Granted Patent US 12,479,853
Granted Patent B2
US 12,479,853 · App. 18/756,256 · Granted Nov 25, 2025

HIV inhibitor compounds

Inventors: Elizabeth M. Bacon (Burlingame, CA); Elbert Chin (San Mateo, CA); Jeromy J. Cottell (Redwood City, CA); Ashley Anne Katana (North Olmstead, OH); Darryl Kato (San Francisco, CA); John O. Link (San Francisco, CA); Nathan Shapiro (Belmont, CA); Teresa Alejandra Trejo Martin (Belmont, CA); Zheng-Yu Yang (Palo Alto, CA)
Assignee: Gilead Sciences, Inc.
C07D487/08A61K31/52A61K31/55A61K31/553A61K31/685A61K31/688A61K45/06A61P31/18C07C243/28C07C275/16C07D401/12C07D403/12C07D405/14C07D471/08C07D487/10C07D491/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,479,853
App. No.
18/756,256
Granted
Nov 25, 2025
Kind
B2
Abstract

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

Claims (10)

1 . A compound selected from:

or a salt thereof.

2 . The compound of claim 1 , which is:

or a salt thereof.

3 . The compound of claim 1 , which is:

or a salt thereof.

4 . The compound of claim 1 , which is selected from

or a salt thereof.

5 . The compound of claim 1 , which is selected from:

or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2024
From: BACON, ELIZABETH M.; CHIN, ELBERT; COTTELL, JEROMY J.; KATANA, ASHLEY ANNE; KATO, DARRYL; LINK, JOHN O.; SHAPIRO, NATHAN; MARTIN, TERESA ALEJANDRA TREJO; YANG, ZHENG-YU
To: GILEAD SCIENCES, INC.
Reel/Frame 069274/0267 →
Continuity (6)
Continuation 17224557 · Apr 7, 2021
Continuation 16805933 · Mar 2, 2020
Continuation 16364487 · Mar 26, 2019
Continuation 15888749 · Feb 5, 2018
Provisional Application 62455348 · Feb 6, 2017
Related Publication 20250042910A1 · Feb 6, 2025
References Cited (208)
US 3845770A · Thecuwes et al. · 1974 [cited by applicant]
US 4326525A · Swanson et al. · 1982 [cited by applicant]
US 4902514A · Barclay et al. · 1990 [cited by applicant]
US 4992445A · Lawter et al. · 1991 [cited by applicant]
US 5001139A · Lawter et al. · 1991 [cited by applicant]
US 5023252A · Hseih · 1991 [cited by applicant]
US 5461067A · Norbeck et al. · 1995 [cited by applicant]
US 5616345A · Geoghegan et al. · 1997 [cited by applicant]
US 5679688A · Grobelny · 1997 [cited by applicant]
US 5753652A · Fassler et al. · 1998 [cited by applicant]
US 5849911A · Fassler et al. · 1998 [cited by applicant]
US 10294234B2 · Bacon et al. · 2019 [cited by applicant]
US 10752636B2 · Bacon et al. · 2020 [cited by applicant]
US 11052087B2 · Chin et al. · 2021 [cited by applicant]
US 11078208B1 · Bacon et al. · 2021 [cited by applicant]
US 12084455B2 · Bacon · 2024 [cited by examiner]
US 20050159469A1 · Randolph et al. · 2005 [cited by applicant]
US 20090076097A1 · Czarnik · 2009 [cited by applicant]
US 20100143301A1 · Desai et al. · 2010 [cited by applicant]
US 20130165489A1 · Cocklin et al. · 2013 [cited by applicant]
US 20130289067A1 · Ghosh et al. · 2013 [cited by applicant]
US 20140221356A1 · Jin et al. · 2014 [cited by applicant]
US 20140221378A1 · Miyazaki et al. · 2014 [cited by applicant]
US 20140221380A1 · Miyazaki et al. · 2014 [cited by applicant]
US 20160002159A1 · Zondlo et al. · 2016 [cited by applicant]
US 20160333009A1 · Bartlett et al. · 2016 [cited by applicant]
US 20170197981A1 · Shaw et al. · 2017 [cited by applicant]
US 20180258097A1 · Bacon et al. · 2018 [cited by applicant]
US 20190308983A1 · Bacon et al. · 2019 [cited by applicant]
US 20200030327A1 · Chin et al. · 2020 [cited by applicant]
US 20230027055A1 · Bacon et al. · 2023 [cited by applicant]
US 20250051375A1 · Brizgys · 2025 [cited by applicant]
AU 2003200066 · 2003 [cited by applicant]
AU 2010276490 · 2012 [cited by applicant]
CN 102190638 · 2011 [cited by applicant]
DE 2847064 · 1980 [cited by applicant]
EP 0521827 · 1993 [cited by applicant]
EP 0604368 · 1994 [cited by applicant]
EP 2003120 · 2008 [cited by applicant]
IN 2008CH01037 · 2016 [cited by applicant]
JP 2007516260 · 2007 [cited by applicant]
JP 2008530045 · 2008 [cited by applicant]
WO WO1993018006 · 1993 [cited by applicant]
WO WO1993022292 · 1993 [cited by applicant]
WO WO1994019332 · 1994 [cited by applicant]
WO WO1997019055 · 1997 [cited by applicant]
WO WO1997040029 · 1997 [cited by applicant]
WO WO1997046514 · 1997 [cited by applicant]
WO WO1998003476 · 1998 [cited by applicant]
WO WO2001004120 · 2001 [cited by applicant]
WO WO2001046120 · 2001 [cited by applicant]
WO WO2002094768 · 2002 [cited by applicant]
WO WO2002100410 · 2002 [cited by applicant]
WO WO2003020370 · 2003 [cited by applicant]
WO WO2003078438 · 2003 [cited by applicant]
WO WO2004096286 · 2004 [cited by applicant]
WO WO2005061450 · 2005 [cited by applicant]
WO WO2005061487 · 2005 [cited by applicant]
WO WO2005087725 · 2005 [cited by applicant]
WO WO2006014282 · 2006 [cited by applicant]
WO WO2006015261 · 2006 [cited by applicant]
WO WO2006110157 · 2006 [cited by applicant]
WO WO2007002172 · 2007 [cited by applicant]
WO WO2007134828 · 2007 [cited by applicant]
WO WO2008011116 · 2008 [cited by applicant]
WO WO2008011117 · 2008 [cited by applicant]
WO WO2008011117A2 · 2008 [cited by examiner]
WO WO2008118849 · 2008 [cited by applicant]
WO WO2008156632 · 2008 [cited by applicant]
WO WO2009062285 · 2009 [cited by applicant]
WO WO2009114151 · 2009 [cited by applicant]
WO WO2009136365 · 2009 [cited by applicant]
WO WO2010022125 · 2010 [cited by applicant]
WO WO2010077317 · 2010 [cited by applicant]
WO WO2010130034 · 2010 [cited by applicant]
WO WO2010132852 · 2010 [cited by applicant]
WO WO2010144869 · 2010 [cited by applicant]
WO WO2011026781 · 2011 [cited by applicant]
WO WO2011080562 · 2011 [cited by applicant]
WO WO2011102964 · 2011 [cited by applicant]
WO WO2012003497 · 2012 [cited by applicant]
WO WO2012003498 · 2012 [cited by applicant]
WO WO2012031237 · 2012 [cited by applicant]
WO WO2012092168 · 2012 [cited by applicant]
WO WO2012092188 · 2012 [cited by applicant]
WO WO2012145728 · 2012 [cited by applicant]
WO WO2012170792 · 2012 [cited by applicant]
WO WO2013006738 · 2013 [cited by applicant]
WO WO2013006792 · 2013 [cited by applicant]
WO WO2013091096 · 2013 [cited by applicant]
WO WO2013159064 · 2013 [cited by applicant]
WO WO2014100323 · 2014 [cited by applicant]
WO WO2014110297 · 2014 [cited by applicant]
WO WO2015061518 · 2015 [cited by applicant]
WO WO2015097667 · 2015 [cited by applicant]
WO WO2015130964 · 2015 [cited by applicant]
WO WO2015175994 · 2015 [cited by applicant]
WO WO2016033243 · 2016 [cited by applicant]
WO WO2016172425 · 2016 [cited by applicant]
WO WO2018053447 · 2018 [cited by applicant]
WO WO2018145021 · 2018 [cited by applicant]
WO WO2020028272 · 2020 [cited by applicant]
WO WO2024249517A1 · 2024 [cited by applicant]
Khagga Bhavyasri, V. Murali Balaram R. Nageswarao, D. Rambabu and M. Ajitha, Int. J. Chem. Sci.: 13(1), 2015, 551-562 (Year: 2015). [cited by examiner]
[No Author], “Transporter Certified Hepatocytes” Qualyst Transporter Solutions, 2012, LLC:1-2. [cited by applicant]
Berge et al., “Pharmaceutical salts,” J. Pharma Sci., 1977, 66(1):1-19. [cited by applicant]
But et al., “The Mitsunobu reaction: origin, mechanism, improvements, and applications,” Chem Asian J., Nov. 2007, 2(11):1340-1355. [cited by applicant]
Chinchilla et al., “The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry,” American Chemical Society, Feb. 2007, 107(3):874-922. [cited by applicant]
Choiu et al., “In Vitro OATP1 B1 and OATP1 B3 Inhibition is Associated With Observations of Benign Clinical Unconjugated Hyperbilirubinemia,” Xenobiotica, Informa Healthcare, 2014, 44(3):276-282. [cited by applicant]
Chu et al. “Species Differences in Drug Transporters and Implications for Translating Preclinical Findings to Humans,” Expert Opinion Drug Metabolism Toxicology, 2013, 9(3):237-252. [cited by applicant]
Cihlar et al., “Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonemediated Solvent Anchoring,” Journal of Molecular Biology, 2006, 363(3):635-647. [cited by applicant]
Croom et al., “Atazanavir—a review of its use in the management of HIV-1 infection,” Drugs, 2009, 69(8):1107-1140. [cited by applicant]
Fassler et al., “Novel pseudosymmetric inhibitors of HIV-1 protease”, Bioorganic & Medicinal Chemistry Letters, Dec. 1993, 3(12):2837-2842. [cited by applicant]
Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci., 5(12):524-527 (1984). [cited by applicant]
Giacomini et al., “Membrane Transporters in Drug Development,” Nature Reviews Drug Development, 2010, 9:215-236. [cited by applicant]
Gillis et al., “Applications of Fluorine in Medicinal Chemistry”, Journal of Medicinal Chemistry, Feb. 2013, 58(21):8315-8359. [cited by applicant]
Kiankarimi et al., “Tetrahedron Letters,” published 1999, 40(24):4497-4500. [cited by applicant]
Link et al., “Novel HIV P1 With High Resistance Barrier and Potential for Unboosted OD Oral dosing”, Abstract, CROI—Conference on Retroviruses and Opportunistic Infections, Seattle, WA: 1-3, 2017. [cited by applicant]
Link et al., “Novel HIV P1 With High Resistance Barrier and Potential for Unboosted OD Oral Dosing,” CROI—Conference on the Retroviruses and Opportunistic Infections, Poster: 1-3, 2017. [cited by applicant]
Link et al., “Novel HIV P1 with High Resistance Barrier and Potential for Unboosted OD Oral Dosing,” Poster; CROI—Conference on Retroviruses and Opportunistic Infections; Poster, 2017, 433: 1-6. [cited by applicant]
Lv et al., “HIV protease inhibitors: a review of molecular selectivity and toxicity,” HIV/AIDS—Research and Palliative Care, 2015, 7:95-104. [cited by applicant]
Morrison, “Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors”, Biochimica et Biophysica Acta (BBA)—Enzymology, Mar. 1969, 185(2):269-286. [cited by applicant]
Rouquayrol et al., “Transepithelial transport of prodrugs of the HIV protease inhibitors Sanquinavir, Indinavir, and Nelfinavir across CaCo-2 cell monolayers,” Pharmaceutical Research, 2002, 19(11):1704-1712. [cited by applicant]
Shah et al., “The role of fluorine in medicinal chemistry”, Journal of Enzyme Inhibition and Medicinal Chemistry, Oct. 2007, 22(5): 527-540. [cited by applicant]
Stella et al., “Prodrugs: Challenges and Rewards Part 1,” Biotechnology: Pharmaceutical Aspects, 2007, 5:33-52. [cited by applicant]
Subbaiah et al., “Design strategies in the prodrugs of HIV-1 protease inhibitors to improve pharmaceutical properties,” European Journal of Medicinal Chemistry, 2017, 139:865-883. [cited by applicant]
Swift et al., “Sandwich-Cultered Hepatocytes: An In Vitro Model to Evaluate Hepatobiliary Transporter-Based Drug Interactions and Hepatotoxicity,” Drug Metabolism Review, 2010, 42(3):1-45. [cited by applicant]
Tanaka et al., “Inhibitors of Acyl-CoA:Cholesterol O-Acytltransferase. 2. Identification and Structure-Activity Relationships of a Novel Series of N-Alkyl-N-(heteroaryl-substituted-benzyl)-N′-arylureas,” J Med. Chem., M… [cited by applicant]
Argentinian Office Action in AR Appln. No. 20180100247, dated Feb. 2, 2022, 9 pages (with English translation). [cited by applicant]
Australian Office Action in AU Appln. No. 2018215546, dated Dec. 19, 2019, 3 pages. [cited by applicant]
Australian Office Action in AU Appln. No. 2019314282, dated Jul. 5, 2021, 3 pages. [cited by applicant]
Australian Office Action in AU Appln. No. 2020264300, dated Mar. 17, 2022, 2 pages. [cited by applicant]
Australian Office Action in AU Patent Application No. 2020264300, dated Aug. 19, 2021, 2 pages. [cited by applicant]
Brazilian Office Action in BR Appln. No. BR102018002152-4, dated Aug. 23, 2022, 7 pages (with English translation). [cited by applicant]
Canadian Office Action in CA Application No. 3,051,588, dated Apr. 30, 2021, 3 pages. [cited by applicant]
Canadian Office Action in CA Appln. No. 3,103,157, dated Feb. 25, 2022, 3 pages. [cited by applicant]
Chilean Office Action in CL appln. No. 201902204, dated Jun. 15, 2020, 25 pages (with English translation). [cited by applicant]
Chilean Office Action in CL Appln. No. 201902204, dated Nov. 16, 2020, 25 pages. [cited by applicant]
Chinese Office Action in CN Appln. No. 201880023198.1, dated Jun. 1, 2022, 16 pages (with English translation). [cited by applicant]
Chinese Office Action in CN Appln. No. 201880023198.1, dated Nov. 23, 2021, 17 pages (with English translation). [cited by applicant]
Chinese Office Action in CN Appln. No. 201980050838.2, dated Nov. 22, 2023, 9 pages (with English translation). [cited by applicant]
Chinese Office Action in CN Appln. No. 202210907879.2, dated Dec. 13, 2023, 9 pages (with English translation). [cited by applicant]
Colombian Notice of Opposition in CO Appln. No. NC2019/0008531, dated Feb. 11, 2020, 14 pages (with English translation). [cited by applicant]
Columbian Office Action in CO Appln. No. NC2019/0008531, dated Feb. 11, 2022, 22 pages (with English translation). [cited by applicant]
Columbian Office Action in CO Appln. No. NC2019/0008531, dated Sep. 20, 2021, 27 pages (with English translation). [cited by applicant]
Costa Rican Office Action in CR Appln. No. 2019-0000354, dated Nov. 8, 2022, 17 pages (with English translation). [cited by applicant]
Dominican Republic Office Action in DO Appln. No. P 2019-0201, dated Oct. 15, 2021, 6 pages (with English translation). [cited by applicant]
Dominican Republic Office Action in DO Appln. No. P-2019-0201, dated Apr. 11, 2022, 6 pages (with English translation). [cited by applicant]
Egyptian Office Action in EG Appln. No. 2019081234, dated May 28, 2023, 8 pages (with English translation). [cited by applicant]
Eurasian Office Action in EA Application No. 201991684, dated Mar. 18, 2021, 2 pages (with English translation). [cited by applicant]
Eurasian Office Action in EA Appln. No. 201991684/28, dated Oct. 1, 2020, 5 pages (with English translation). [cited by applicant]
European Office Action in EP Appln. No. 19752359.0, dated Apr. 6, 2022, 5 pages. [cited by applicant]
European Office Action in European Application No. 18706072, dated Sep. 25, 2019, 14 pages. [cited by applicant]
Extended European Search Report in EP Application No. 21165835.6, dated Oct. 15, 2021, 14 pages. [cited by applicant]
Gulf Coop Council Office Action in GC Appln. No. 2019-37997, dated Jul. 28, 2020, 4 pages. [cited by applicant]
Gulf Coop Council Office Action in GC Appln. No. 2019-37997, dated Nov. 29, 2020, 3 pages. [cited by applicant]
Gulf Co-Operation Examination Report in GC Application No. 34714, dated Jul. 25, 2022, 4 pages. [cited by applicant]
Gulf Co-Operation Office Action in GC Application No. 34714, dated May 20, 2021, 4 pages. [cited by applicant]
Indian Office Action in IN Appln. No. 201917032272, dated Mar. 4, 2020, 4 pages (with English translation). [cited by applicant]
Indian Office Action in IN Appln. No. 202017056385, dated Jul. 30, 2021, 6 pages. [cited by applicant]
Indonesian Office Action in ID Appln. No. P00201907796, dated Oct. 26, 2023, 5 pages (with English translation). [cited by applicant]
Indonesian Office Action in ID Appln. No. P00201907796, dated Sep. 21, 2021, 9 pages (with English translation). [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2018/016893, dated Aug. 15, 2019, 8 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2019/043965, dated Feb. 2, 2021, 7 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2018/016893, dated Apr. 24, 2018, 12 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2019/043965, dated Oct. 14, 2019, 8 pages. [cited by applicant]
Israeli Office Action in IL Appln. No. 268282, dated Jul. 18, 2021, 6 pages (with English translation). [cited by applicant]
Japanese Office Action in JP Appln. No. 2019-542392, dated Oct. 6, 2020, 6 pages (with English translation). [cited by applicant]
Japanese Office Action in JP Appln. No. 2020-200176, dated Feb. 3, 2022, 5 pages (with English translation). [cited by applicant]
Japanese Office Action in JP Appln. No. 2021-016635, dated Jan. 11, 2023, 6 pages (with English translation). [cited by applicant]
Japanese Office Action in JP Appln. No. 2021-016635, dated Mar. 3, 2022, 4 pages (with English translation). [cited by applicant]
Japanese Office Action in JP Appln. No. 2021-504759, dated Apr. 18, 2022, 6 pages (with English translation). [cited by applicant]
Korean Office Action in KR Appln. No. 10-2019-7025847, dated Aug. 4, 2021, 5 pages (with English translation). [cited by applicant]
Korean Office Action in KR Appln. No. 10-2019-7025847, dated Feb. 26, 2021, 10 pages (with English translation). [cited by applicant]
Mexican Office Action in MX Appln. No. MX/a/2019/009212, dated Aug. 2, 2022, 5 pages (with English translation). [cited by applicant]
Mexican Office Action in MX Appln. No. MX/a/2019/009212, dated Mar. 7, 2022, 8 pages (with English translation). [cited by applicant]
Mexican Office Action in MX Appln. No. MX/a/2019/009212, dated May 17, 2022, 5 pages (with English translation). [cited by applicant]
New Zealand Office Action in NZ Appln. No. 755929, dated Nov. 13, 2020, 5 pages. [cited by applicant]
Office Action in Costa Rican Appln. No. 2019000354, dated Nov. 28, 2023, 13 pages (with English translation). [cited by applicant]
Office Action in Peruvian Appln. No. 001536-2019/DIN, dated Jan. 31, 2024, 16 pages (with English translation). [cited by applicant]
Philippine Office Action in PH Appln. No. 1-2019-501786, dated May 25, 2022, 5 pages. [cited by applicant]
Philippine Office Action in PH Appln. No. 1-2019-501786, dated Sep. 21, 2023, 4 pages. [cited by applicant]
Philippine Office Action in PH Appln. No. 1-2019-501786, dated Sep. 8, 2022, 5 pages. [cited by applicant]
Saudi Arabian Office Action in SA Appln No. 519402405, dated Jan. 27, 2022, 9 pages (Machine English translation). [cited by applicant]
Saudi Arabian Office Action in SA Appln No. 519402405, dated Oct. 20, 2022, 9 pages (Machine English translation). [cited by applicant]
Saudi Arabian Office Action in SA Appln. No. 523442077, dated Jun. 22, 2023, 9 pages (with English translation). [cited by applicant]
Saudi Arabian Office Action in SA Appln. No. 523442077, dated Nov. 11, 2023, 8 pages (with English translation). [cited by applicant]
Taiwanese Office Action in TW Application No. 107103968, dated Dec. 3, 2019. 7 pages (with English translation). [cited by applicant]
Taiwanese Office Action in TW Application No. 107103968, dated Jan. 29, 2019, 9 pages. [cited by applicant]
Taiwanese Office Action in TW Appln. No. 108124043, dated May 11, 2020, 7 pages (with English translation). [cited by applicant]
Taiwanese Office Action in TW Appln. No. 108124043, dated Oct. 6, 2020, 5 pages (with English translation). [cited by applicant]
Taiwanese Office Action in TW Appln. No. 108124043, dated Sep. 2, 2021, 25 pages (with English translation). [cited by applicant]
Taiwanese Office Action in TW Appln. No. 109126112, dated Feb. 23, 2022, 10 pages (with English translation). [cited by applicant]
Taiwanese Office Action in TW Appln. No. 112103166, dated Oct. 16, 2023, 12 pages (with English translation). [cited by applicant]
Third Party Observation in International Application No. PCT/US2018/016893, dated Jun. 7, 2019, 10 pages. [cited by applicant]
Third Party Observation in International Appln. No. PCT/US2019/043965, dated Nov. 30, 2020, 9 pages. [cited by applicant]
Ukrainian Office Action in UA Appln. No. a2019 09440, dated Sep. 21, 2020, 5 pages (with English translation). [cited by applicant]
Uzbekistan Office Action in UZ Appln. No. IAP 20190371, dated Dec. 17, 2021, 4 pages (with English translation). [cited by applicant]
Uzbekistan Office Action in UZ Appln. No. IAP 20190371, dated Jun. 7, 2022, 15 pages (with English translation). [cited by applicant]
Vietnamese Office Action in VN Appln. No. 1-2019-04616, dated Aug. 3, 2023, 4 pages (with English translation). [cited by applicant]
Chinese Office Action in CN Appln. No. 202210907879.2, dated Nov. 29, 2024, 12 pages (with English translation). [cited by applicant]
New Zealand Office Action in NZ Appln. No. 776008, dated Dec. 20, 2024, 4 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2024/031478, dated Oct. 22, 2024, 13 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2025/022817, dated May 27, 2025, 14 pages. [cited by applicant]
Office Action in Malaysian Appln. No. PI2023007993, mailed Jan. 9, 2025, 2 pages. [cited by applicant]
Office Action in Mexican Appln. No. MX/a/2022/012616, mailed Apr. 3, 2025, 8 pages (with English translation). [cited by applicant]
Office Action in Taiwanese Appln. No. 113128501, mailed Apr. 11, 2025, 22 pages. [cited by applicant]
STN Registry No. 1824136-67-5, “3,8-Diazabi cyclo[3.2.1]octane, 3-(2-pyrimidinyl),” dated Dec. 7, 2015, 1 page. [cited by applicant]